CA-LEGENDARY-PICTURES
25.8.2022 16:02:11 CEST | Business Wire | Press release
Coming off the global success of 2021’s “Godzilla vs Kong” cameras are now rolling on the latest entry in Warner Bros. Pictures’ and Legendary Pictures’ cinematic Monsterverse. This latest entry follows up the explosive showdown of Godzilla vs. Kong with an all-new cinematic adventure, pitting the almighty Kong and the fearsome Godzilla against a colossal undiscovered threat hidden within our world, challenging their very existence – and our own. The epic new film will delve further into the histories of these Titans, their origins and the mysteries of Skull Island and beyond, while uncovering the mythic battle that helped forge these extraordinary beings and tied them to humankind forever.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220825005274/en/
The film, which recently began principal photography, is again being helmed by director Adam Wingard (“You’re Next” “The Guest”) and stars returning cast members Rebecca Hall (“The Night House” “Resurrection”), Brian Tyree Henry (“Bullet Train” “Atlanta”), and Kaylee Hottle (“Godzilla vs. Kong”), who are now joined by newcomers Dan Stevens (“Gaslit” “Legion” “Beauty and the Beast”), Fala Chen (“Irma Vep” “Shang Chi and the Legend of the Ten Rings”), Alex Ferns (“The Batman” “Wrath of Man” “Chernobyl”) and Rachel House (“Hunt for the Wilderpeople” “Thor: Ragnarok” “Foundation”).
Wingard is directing the currently untitled project from a script by Terry Rossio (“Godzilla vs. Kong” the “Pirates of the Caribbean” series), Jeremy Slater (“Moon Knight”) and Simon Barrett (“You’re Next”). The film is being produced by Mary Parent, Alex Garcia, Eric Mcleod, Brian Rogers, Thomas Tull, and Jon Jashni, with executive producers Josh Grode, Adam Wingard, Jay Ashenfelter, Jen Conroy, Kenji Okuhira and Yoshimitsu Banno.
Once again, Wingard is collaborating with director of photography Ben Seresin (“Godzilla vs. Kong” “World War Z”), production designer Tom Hammock (“Godzilla vs. Kong” “X” “The Guest”), editor Josh Schaeffer (“Godzilla vs. Kong” “Molly’s Game”), and composer Tom Holkenborg (“Godzilla vs. Kong” “Mad Max: Fury Road”), who are now joined by costume designer Emily Seresin (“The Invisible Man” “Top of the Lake”), makeup artist Sabrina Wilson (“Captain Marvel” “The Suicide Squad” “The Book of Bobba Fett”), hairstylist Gloria Pasqua Casny (“The Tomorrow War” “Ford vs Ferrari”), and VFX supervisor Alessandro Ongaro (“The Adam Project” “Ghostbusters: Afterlife”).
The film is being shot on location in Queensland, Australia and is slated for a March 15, 2024, worldwide release from Warner Bros. Pictures except in Japan where it will be distributed by Toho Co., Ltd and in mainland China where it will be distributed by Legendary East.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220825005274/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
T964 Named as Uptime Institute Business Partner to Power Iraq’s Digital Infrastructure29.7.2026 09:02:00 CEST | Press release
Agreement signed at U.S.-Iraq Business Summit brings the world’s most trusted digital infrastructure standards to Iraq Uptime Institute and Tech964 Holding Limited (T964), Iraq’s leading digital infrastructure company, today announced a landmark strategic partnership to accelerate Iraq’s digital transformation. The partnership combines the world’s leading authority in digital infrastructure standards with the company building the critical infrastructure underpinning Iraq’s digital economy. The agreement was signed at the U.S. Chamber of Commerce U.S.-Iraq Business Summit on July 17, 2026, during the official U.S. visit of Iraqi Prime Minister Ali Al-Zaidi, at a historic summit that produced more than 50 agreements valued at over USD $60 billion and marked a powerful new era of economic cooperation between the United States and Iraq. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728066813/en/ T964 named as Uptime Institut
ELFA Vape Aerosols Less Harmful Than Cigarette Smoke: Study29.7.2026 09:00:00 CEST | Press release
Levels of 17 analytes usually found in cigarette smoke tested in aerosols from ELFBAR ELFA pods 10 harmful constituents below detectable levels, with formaldehyde and acetaldehyde up to 99.9%* lower than those in cigarette smoke Metals detected well below safety thresholds Complete switching to ELFA significantly reduces or brings to zero adult users’ exposure to harmful constituents Levels of 17 constituents in aerosols from ELFA, a pod system vape by ELFBAR, are undetected or substantially lower than those in cigarette smoke, reveals the latest peer-reviewed study published by iScience, a scientific journal. Aerosols in this study are generated by facilities under standardized laboratory conditions. The tests involve 17 cigarette smoke-related analytes during vaporization of vape liquid from ELFA’s pods in four flavors, including Super Tobacco, Spearmint, Strawberry Ice and Watermelon. Findings indicate that adult smokers completely transitioning to ELFA pod system could reduce, or e
PK MED Strengthens Its Strategic and Scientific Governance to Support the Development of Its Therapeutic Micro-implants29.7.2026 09:00:00 CEST | Press release
François Romaneix is appointed Chairman of the Board of Directors.Prof. Philippe Leboulch joins the Board of Directors and the Scientific Advisory Board.Prof. Alain Fischer becomes Chairman of the Scientific Advisory Board.Isabelle Buckle and Tom Tice are appointed to the Board of Directors. PK MED, a French biotechnology company founded by Truffle Capital (founder of Abivax and Carvolix), developing therapeutic micro-implants to address major medical needs, today announces a significant strengthening of its governance. The company is strengthening the structure of its Board of Directors and Scientific Advisory Board to support the upcoming Phase 2 entry of its most advanced drug candidate, ARTHRELIS (treatment of gout flares), and to accelerate the preclinical development of ENGRAFTIS (treatment of poor graft function following bone marrow transplantation). The Board of Directors of PK MED welcomes four key new members: François Romaneix, appointed Chairman of the Board of Directors.
OpenGate Capital Executes Agreement to Acquire Merak, the Global Rail HVAC Business of Knorr-Bremse29.7.2026 08:00:00 CEST | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Merak, the global rail HVAC business of Knorr-Bremse, a publicly listed German industrial company. Terms of the transaction were not disclosed. Headquartered in Getafe, Spain, Merak is a leading global provider of HVAC systems for rail vehicles, with facilities across Spain, Austria, Australia, the United States, China and India. The company offers a comprehensive portfolio of HVAC solutions spanning original equipment, aftermarket services, spare parts, system modernization and overhaul. Built on more than 60 years of engineering expertise, Merak serves a global installed base and maintains long standing relationships with many of the world's leading rolling stock manufacturers. "Merak is a high quality business with a market leading position, differentiated technology and a global customer base built over decades," said Joshua Adams, Partner at OpenGate Ca
Bureau Veritas: Delivering on Our Commitments With Higher Sequential Organic Growth in Q2 and Continuous Margin Improvements29.7.2026 07:30:00 CEST | Press release
Bureau Veritas (BOURSE:BVI): H1 2026 key figures1 › Revenue of EUR 3,258.4 million in H1 2026, up 2.1% year-on-year and up 5.0% organically (with a sequential improvement in Q2 2026 at 5.5% organic growth), › Adjusted operating profit of EUR 506.5 million, up 3.1% versus EUR 491.5 million in H1 2025, representing an adjusted operating margin of 15.5%, up 15 basis points year-on-year and up 29 basis points at constant currency, › Operating profit of EUR 430.8 million, down 16.0% versus EUR 513.1 million in H1 20252, › Adjusted net profit of EUR 303.8 million, up 3.9% versus EUR 292.4 million in H1 2025, › Adjusted EPS stood at EUR 0.68 in H1 2026, with a 4.8% increase on a reported basis versus H1 2025 (EUR 0.65 per share) and 9.8% at constant currency, › Attributable net profit of EUR 237.9 million, down 26.2% versus EUR 322.3 in H1 2025, › Free Cash Flow of EUR 157.7 million, up 3.2% organically, and down 6.1% year-on-year due to forex evolutions, › Adjusted net debt/EBITDA ratio stoo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom